Novo Nordisk (0QIU) Share Forecast & Price Target

Compare

73 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0QIU Analyst Ratings

Moderate Buy

6 Buy

5 Hold

1 Sell

Based on 12 analysts giving stock ratings to

Novo

Nordisk

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0QIU Stock 12 Month Forecast

Average Price Target

kr375.18

▲(22.63% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Novo Nordisk in the last 3 months. The average price target is kr375.18 with a high forecast of kr540.00 and a low forecast of kr270.00. The average price target represents a 22.63% change from the last price of kr305.94.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"269":"kr269","508":"kr508","747":"kr747","388.5":"kr388.5","627.5":"kr627.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":540,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr540.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":375.18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr375.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":270,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr270.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[269,388.5,508,627.5,747],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,313.59,331.00615384615384,348.42230769230764,365.8384615384615,383.25461538461536,400.6707692307692,418.0869230769231,435.5030769230769,452.91923076923075,470.3353846153846,487.7515384615384,505.1676923076923,522.5838461538461,{"y":540,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,313.59,318.3276923076923,323.0653846153846,327.8030769230769,332.54076923076923,337.2784615384615,342.0161538461538,346.75384615384615,351.4915384615384,356.22923076923075,360.9669230769231,365.7046153846154,370.4423076923077,{"y":375.18,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,313.59,310.23692307692306,306.88384615384615,303.53076923076924,300.17769230769227,296.82461538461536,293.47153846153844,290.11846153846153,286.7653846153846,283.4123076923077,280.0592307692308,276.7061538461538,273.3530769230769,{"y":270,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":746.74,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":604.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":594.7,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":623.09,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":475.89,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":426.72,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":469.51,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":427.78,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":300.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":368.59,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":355.64,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":315.27,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":313.59,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Targetkr540.00

Average Price Targetkr375.18

Lowest Price Targetkr270.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Emmanuel Papadakis

Deutsche Bank

kr475

Buy

55.26%

Upside

Reiterated

12/16/25

Novo Nordisk (0QIU) Receives a Buy from Deutsche Bank

Richard Vosser

J.P. Morgan

kr350

Buy

14.40%

Upside

Reiterated

12/16/25

J.P. Morgan Reaffirms Their Buy Rating on Novo Nordisk (0QIU)

David Evans

Kepler Capital

kr510→kr430

Buy

40.55%

Upside

Reiterated

12/15/25

Novo Nordisk (0QIU) Receives a Buy from Kepler Capital

Matthew Weston

UBS

kr295

Hold

-3.58%

Downside

Reiterated

12/12/25

UBS Remains a Hold on Novo Nordisk (0QIU)

James Quigley

Goldman Sachs

kr353→kr352

Buy

15.06%

Upside

Reiterated

12/09/25

Goldman Sachs Sticks to Their Buy Rating for Novo Nordisk (0QIU)

Kerry Holford

Berenberg Bank

kr400

Buy

30.74%

Upside

Reiterated

12/05/25

Berenberg Bank Keeps Their Buy Rating on Novo Nordisk (0QIU)

Sachin Jain

Bank of America Securities

kr315→kr340

Hold

11.13%

Upside

Reiterated

12/01/25

Novo Nordisk (0QIU) Receives a Hold from Bank of America Securities

Michael Leuchten

Jefferies

kr290→kr270

Sell

-11.75%

Downside

Reiterated

12/01/25

Novo Nordisk (0QIU) Receives a Sell from Jefferies

Yihan Li

Barclays

kr375

Hold

22.57%

Upside

Reiterated

11/28/25

Barclays Sticks to Their Hold Rating for Novo Nordisk (0QIU)

Rajesh Kumar

HSBC

kr300

Hold

-1.94%

Downside

Downgraded

11/24/25

Novo Nordisk downgraded to Hold from Buy at HSBCNovo Nordisk downgraded to Hold from Buy at HSBC

Elmar Kraus

DZ BANK AG

Hold

―

Reiterated

11/24/25

DZ BANK AG Sticks to Their Hold Rating for Novo Nordisk (0QIU)

Florent Cespedes

Bernstein

kr540

Buy

76.51%

Upside

Reiterated

11/04/25

Bernstein Sticks to Its Buy Rating for Novo Nordisk (0QIU)

Nico Chen

DBS

kr340

Hold

11.13%

Upside

Upgraded

08/22/25

Novo Nordisk upgraded to Hold from Sell at DBS BankNovo Nordisk upgraded to Hold from Sell at DBS Bank

Martial Descoutures

Oddo BHF

kr465

Hold

51.99%

Upside

Downgraded

07/30/25

Novo Nordisk downgraded to Neutral from Outperform at Oddo BHFNovo Nordisk downgraded to Neutral from Outperform at Oddo BHF

Thibault Boutherin

Morgan Stanley

kr550

Hold

79.77%

Upside

Reiterated

06/23/25

Morgan Stanley Reaffirms Their Hold Rating on Novo Nordisk (0QIU)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Emmanuel Papadakis

Deutsche Bank

kr475

Buy

55.26%

Upside

Reiterated

12/16/25

Novo Nordisk (0QIU) Receives a Buy from Deutsche Bank

Richard Vosser

J.P. Morgan

kr350

Buy

14.40%

Upside

Reiterated

12/16/25

J.P. Morgan Reaffirms Their Buy Rating on Novo Nordisk (0QIU)

David Evans

Kepler Capital

kr510→kr430

Buy

40.55%

Upside

Reiterated

12/15/25

Novo Nordisk (0QIU) Receives a Buy from Kepler Capital

Matthew Weston

UBS

kr295

Hold

-3.58%

Downside

Reiterated

12/12/25

UBS Remains a Hold on Novo Nordisk (0QIU)

James Quigley

Goldman Sachs

kr353→kr352

Buy

15.06%

Upside

Reiterated

12/09/25

Goldman Sachs Sticks to Their Buy Rating for Novo Nordisk (0QIU)

Kerry Holford

Berenberg Bank

kr400

Buy

30.74%

Upside

Reiterated

12/05/25

Berenberg Bank Keeps Their Buy Rating on Novo Nordisk (0QIU)

Sachin Jain

Bank of America Securities

kr315→kr340

Hold

11.13%

Upside

Reiterated

12/01/25

Novo Nordisk (0QIU) Receives a Hold from Bank of America Securities

Michael Leuchten

Jefferies

kr290→kr270

Sell

-11.75%

Downside

Reiterated

12/01/25

Novo Nordisk (0QIU) Receives a Sell from Jefferies

Yihan Li

Barclays

kr375

Hold

22.57%

Upside

Reiterated

11/28/25

Barclays Sticks to Their Hold Rating for Novo Nordisk (0QIU)

Rajesh Kumar

HSBC

kr300

Hold

-1.94%

Downside

Downgraded

11/24/25

Novo Nordisk downgraded to Hold from Buy at HSBCNovo Nordisk downgraded to Hold from Buy at HSBC

Elmar Kraus

DZ BANK AG

Hold

―

Reiterated

11/24/25

DZ BANK AG Sticks to Their Hold Rating for Novo Nordisk (0QIU)

Florent Cespedes

Bernstein

kr540

Buy

76.51%

Upside

Reiterated

11/04/25

Bernstein Sticks to Its Buy Rating for Novo Nordisk (0QIU)

Nico Chen

DBS

kr340

Hold

11.13%

Upside

Upgraded

08/22/25

Novo Nordisk upgraded to Hold from Sell at DBS BankNovo Nordisk upgraded to Hold from Sell at DBS Bank

Martial Descoutures

Oddo BHF

kr465

Hold

51.99%

Upside

Downgraded

07/30/25

Novo Nordisk downgraded to Neutral from Outperform at Oddo BHFNovo Nordisk downgraded to Neutral from Outperform at Oddo BHF

Thibault Boutherin

Morgan Stanley

kr550

Hold

79.77%

Upside

Reiterated

06/23/25

Morgan Stanley Reaffirms Their Hold Rating on Novo Nordisk (0QIU)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novo Nordisk

1 Month

xxx

Success Rate

39/64 ratings generated profit

Average Return

+1.11%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.94% of your transactions generating a profit, with an average return of +1.11% per trade.

3 Months

xxx

Success Rate

14/23 ratings generated profit

Average Return

-0.46%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.87% of your transactions generating a profit, with an average return of -0.46% per trade.

1 Year

Richard VosserJ.P. Morgan

Success Rate

43/64 ratings generated profit

Average Return

+13.90%

reiterated a buy rating 8 days ago

Copying Richard Vosser's trades and holding each position for 1 Year would result in 67.19% of your transactions generating a profit, with an average return of +13.90% per trade.

2 Years

xxx

Success Rate

17/23 ratings generated profit

Average Return

-7.93%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 73.91% of your transactions generating a profit, with an average return of -7.93% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0QIU Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0QIU has received 29 Buy Ratings, 17 Hold Ratings, and 4 Sell Ratings. 0QIU average Analyst price target in the past 3 months is 375.18.

Each month's total comprises the sum of three months' worth of ratings.

0QIU Financial Forecast

0QIU Earnings Forecast

Next quarter’s earnings estimate for 0QIU is kr5.89 with a range of kr5.30 to kr6.35. The previous quarter’s EPS was kr4.50. 0QIU beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 0QIU has Performed in-line its overall industry.

0QIU Sales Forecast

Next quarter’s sales forecast for 0QIU is kr76.94B with a range of kr72.74B to kr82.65B. The previous quarter’s sales results were kr74.98B. 0QIU beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 0QIU has Performed in-line its overall industry.

0QIU Stock Forecast FAQ

What is GB:0QIU’s average 12-month price target, according to analysts?

Based on analyst ratings, Novo Nordisk’s 12-month average price target is 375.18.

What is GB:0QIU’s upside potential, based on the analysts’ average price target?

Novo Nordisk has 22.63% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Novo Nordisk a Buy, Sell or Hold?

Novo Nordisk has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 5 hold ratings and 1 sell ratings.

What is Novo Nordisk’s share price target?

The average share price target for Novo Nordisk is 375.18. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is kr540.00 ,and the lowest forecast is kr270.00. The average share price target represents 22.63% Increase from the current price of kr305.94.

What do analysts say about Novo Nordisk?

Novo Nordisk’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of Novo Nordisk?

To buy shares of GB:0QIU, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Novo Nordisk (0QIU) Share Forecast & Price Target

0QIU Analyst Ratings

0QIU Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Novo Nordisk

0QIU Analyst Recommendation Trends

0QIU Financial Forecast

0QIU Earnings Forecast

0QIU Sales Forecast

0QIU Stock Forecast FAQ

Detailed List of Analyst Forecasts